Jupiter Neurosciences Announces Direct Stock Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Source: Newsfilter
- Stock Offering Plan: Jupiter Neurosciences has signed a securities purchase agreement to issue 7,142,858 shares of common stock, aiming to raise approximately $2 million, thereby enhancing its R&D capabilities in central nervous system disorders.
- Underwriter Role: D. Boral Capital LLC has been appointed as the exclusive placement agent for this offering, ensuring a smooth fundraising process and further enhancing the company's market credibility and investor confidence.
- Registration Statement Validity: The stock offering is based on an effective shelf registration statement approved by the SEC on April 24, 2026, indicating the company's transparency and compliance, which boosts investor trust.
- Clinical Trial Progress: Jupiter's lead program, JOTROL(TM), is currently in a Phase IIa clinical trial for Parkinson's disease, and the successful fundraising will provide essential financial support for its R&D, aiding the company's long-term growth in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JUNS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JUNS
Wall Street analysts forecast JUNS stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.256
Low
25.00
Averages
25.00
High
25.00
Current: 0.256
Low
25.00
Averages
25.00
High
25.00
About JUNS
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jupiter Neurosciences Launches JOTROL™ Clinical Trial for Parkinson's Disease
- Trial Launch: Jupiter Neurosciences has announced the commencement of patient enrollment in its Phase 2a RESET clinical trial (NCT07592767) for JOTROL™, with first patient dosing expected soon, marking a significant advancement in the field of neurodegenerative diseases.
- Market Potential: With approximately 1.1 million Parkinson's disease patients in the U.S. and around 90,000 new diagnoses annually, the economic burden of $82.2 billion underscores the urgent need for effective therapies, which JOTROL™ aims to address.
- Drug Profile Advantage: JOTROL™ demonstrated approximately 9-fold higher bioavailability compared to conventional resveratrol in Phase 1 studies (Cmax 455 ng/mL vs. 85 ng/mL), indicating its potential advantages in central nervous system exposure, which could offer new treatment options for Parkinson's patients.
- Research Milestone: The initiation of this trial represents a culmination of ten years of research at Jupiter, with CEO Christer Rosén expressing anticipation for clinical data to evaluate JOTROL™'s potential to meet the needs of patients and healthcare providers.
See More
Jupiter Neurosciences Announces Stock Purchase Agreement
- Stock Purchase Agreement: Jupiter Neurosciences has entered into a security purchase agreement to sell 7,142,858 shares at $0.28 each, aiming for gross proceeds of $2 million, despite shares hitting a 52-week low of $0.17, indicating market concerns about the company's outlook.
- Clinical Trial Progress: The company is advancing JOTROL, a proprietary resveratrol formulation for Parkinson's disease in a Phase 2a trial, which, if successful, could enhance its competitive position in the biopharmaceutical sector.
- Product Diversification: In addition to JOTROL, Jupiter is commercializing Nugevia, a consumer longevity supplement, and has acquired licensing rights for ALA-002 MDMA therapy, indicating an intent to expand into the psychedelic drug space, potentially driving future revenue growth.
- Stock Price Volatility: Despite a 35.94% drop to $0.20 at Wednesday's close, shares rebounded 31.22% to $0.27 in after-hours trading, reflecting mixed market sentiments regarding the company's future potential.
See More
Jupiter Neurosciences Announces Direct Stock Offering
- Stock Offering Plan: Jupiter Neurosciences has signed a securities purchase agreement to issue 7,142,858 shares of common stock, aiming to raise approximately $2 million, thereby enhancing its R&D capabilities in central nervous system disorders.
- Underwriter Role: D. Boral Capital LLC has been appointed as the exclusive placement agent for this offering, ensuring a smooth fundraising process and further enhancing the company's market credibility and investor confidence.
- Registration Statement Validity: The stock offering is based on an effective shelf registration statement approved by the SEC on April 24, 2026, indicating the company's transparency and compliance, which boosts investor trust.
- Clinical Trial Progress: Jupiter's lead program, JOTROL(TM), is currently in a Phase IIa clinical trial for Parkinson's disease, and the successful fundraising will provide essential financial support for its R&D, aiding the company's long-term growth in the biopharmaceutical sector.
See More
PharmAla Grants Exclusive U.S. License to Jupiter for ALA-002
- Transaction Value Exceeds $100M: PharmAla Biotech Holdings Inc. has entered a term sheet with Jupiter Neurosciences, which proposes a transaction exceeding $100 million, including upfront payments, development milestone payments, and single-digit royalties on net sales, indicating strong market potential in the biotech sector.
- Upfront Payment Details: Upon closing the definitive agreement, PharmAla will receive $3.33 million in upfront consideration, comprising $1.50 million in cash and $1.83 million in Jupiter common stock, subject to a 10-day lock-up period, providing the company with short-term liquidity.
- Market Development Platform: The transaction aims to provide ALA-002 with a dedicated U.S. development and commercialization platform through Jupiter Neurosciences, highlighting PharmAla's strategic positioning in the CNS sector and enhancing its competitive edge in the market.
- Retention of International Rights: PharmAla will retain all rights to ALA-002 outside the United States, including its existing commercial presence through the Cortexa joint venture in Australia, ensuring continued growth in global markets.
See More
Jupiter Signs Licensing Agreement for MDMA Drug
- Agreement Value: Jupiter's licensing agreement with PharmAla Biotech has a potential value of up to $100 million, with an upfront payment of $3.3 million, including $1.5 million in cash and $1.83 million in stock, reflecting the company's confidence in future drug development.
- Innovative Drug Development: ALA-002, a patented MDMA formulation recognized by the FDA, aims to improve cardiovascular safety and reduce abuse risks while maintaining the therapeutic effects associated with MDMA-assisted treatment, potentially playing a pivotal role in future neuropsychiatric therapies.
- Market Potential: This deal positions Jupiter to capitalize on the rapidly growing psychedelic therapeutics market, which is expected to evolve into a multi-billion-dollar industry in the U.S., indicating the company's strategic focus on emerging medical fields.
- Positive Stock Reaction: Shares of JUNS surged over 50% in early trading, marking the largest single-day gain in nearly a year, with retail sentiment shifting from neutral to extremely bullish, demonstrating strong investor confidence in the company's future prospects.
See More
UK Launches Investment Campaign Featuring Savvy the Squirrel
- Campaign Launch: Chancellor Rachel Reeves and CEO Julia Hoggett of the London Stock Exchange have initiated a £20 million investment campaign aimed at encouraging more Britons to invest, with expectations of significantly enhancing public awareness of investment over the next three years.
- Target Audience Defined: The campaign specifically targets approximately 7 million adults holding over £10,000 in cash savings, aiming to shift their perception of investing and reduce the tendency to leave funds idle in cash, thereby driving economic growth and improving personal financial security.
- Broad Industry Support: The initiative has garnered backing from major financial institutions, including Hargreaves Lansdown and St James's Place, demonstrating a collective effort within the financial services sector to elevate investment awareness and strengthen industry collaboration.
- Rich Historical Context: The launch of this campaign starkly contrasts with the investment boom of the 1980s, when the UK government spurred public interest in stock investments through privatization policies, reflecting the evolving investment culture and its potential economic implications today.
See More
Jupiter Neurosciences Launches JOTROL™ Clinical Trial for Parkinson's Disease
- Trial Launch: Jupiter Neurosciences has announced the commencement of patient enrollment in its Phase 2a RESET clinical trial (NCT07592767) for JOTROL™, with first patient dosing expected soon, marking a significant advancement in the field of neurodegenerative diseases.
- Market Potential: With approximately 1.1 million Parkinson's disease patients in the U.S. and around 90,000 new diagnoses annually, the economic burden of $82.2 billion underscores the urgent need for effective therapies, which JOTROL™ aims to address.
- Drug Profile Advantage: JOTROL™ demonstrated approximately 9-fold higher bioavailability compared to conventional resveratrol in Phase 1 studies (Cmax 455 ng/mL vs. 85 ng/mL), indicating its potential advantages in central nervous system exposure, which could offer new treatment options for Parkinson's patients.
- Research Milestone: The initiation of this trial represents a culmination of ten years of research at Jupiter, with CEO Christer Rosén expressing anticipation for clinical data to evaluate JOTROL™'s potential to meet the needs of patients and healthcare providers.
See More
Jupiter Neurosciences Announces Stock Purchase Agreement
- Stock Purchase Agreement: Jupiter Neurosciences has entered into a security purchase agreement to sell 7,142,858 shares at $0.28 each, aiming for gross proceeds of $2 million, despite shares hitting a 52-week low of $0.17, indicating market concerns about the company's outlook.
- Clinical Trial Progress: The company is advancing JOTROL, a proprietary resveratrol formulation for Parkinson's disease in a Phase 2a trial, which, if successful, could enhance its competitive position in the biopharmaceutical sector.
- Product Diversification: In addition to JOTROL, Jupiter is commercializing Nugevia, a consumer longevity supplement, and has acquired licensing rights for ALA-002 MDMA therapy, indicating an intent to expand into the psychedelic drug space, potentially driving future revenue growth.
- Stock Price Volatility: Despite a 35.94% drop to $0.20 at Wednesday's close, shares rebounded 31.22% to $0.27 in after-hours trading, reflecting mixed market sentiments regarding the company's future potential.
See More
Jupiter Neurosciences Announces Direct Stock Offering
- Stock Offering Plan: Jupiter Neurosciences has signed a securities purchase agreement to issue 7,142,858 shares of common stock, aiming to raise approximately $2 million, thereby enhancing its R&D capabilities in central nervous system disorders.
- Underwriter Role: D. Boral Capital LLC has been appointed as the exclusive placement agent for this offering, ensuring a smooth fundraising process and further enhancing the company's market credibility and investor confidence.
- Registration Statement Validity: The stock offering is based on an effective shelf registration statement approved by the SEC on April 24, 2026, indicating the company's transparency and compliance, which boosts investor trust.
- Clinical Trial Progress: Jupiter's lead program, JOTROL(TM), is currently in a Phase IIa clinical trial for Parkinson's disease, and the successful fundraising will provide essential financial support for its R&D, aiding the company's long-term growth in the biopharmaceutical sector.
See More
PharmAla Grants Exclusive U.S. License to Jupiter for ALA-002
- Transaction Value Exceeds $100M: PharmAla Biotech Holdings Inc. has entered a term sheet with Jupiter Neurosciences, which proposes a transaction exceeding $100 million, including upfront payments, development milestone payments, and single-digit royalties on net sales, indicating strong market potential in the biotech sector.
- Upfront Payment Details: Upon closing the definitive agreement, PharmAla will receive $3.33 million in upfront consideration, comprising $1.50 million in cash and $1.83 million in Jupiter common stock, subject to a 10-day lock-up period, providing the company with short-term liquidity.
- Market Development Platform: The transaction aims to provide ALA-002 with a dedicated U.S. development and commercialization platform through Jupiter Neurosciences, highlighting PharmAla's strategic positioning in the CNS sector and enhancing its competitive edge in the market.
- Retention of International Rights: PharmAla will retain all rights to ALA-002 outside the United States, including its existing commercial presence through the Cortexa joint venture in Australia, ensuring continued growth in global markets.
See More
Jupiter Signs Licensing Agreement for MDMA Drug
- Agreement Value: Jupiter's licensing agreement with PharmAla Biotech has a potential value of up to $100 million, with an upfront payment of $3.3 million, including $1.5 million in cash and $1.83 million in stock, reflecting the company's confidence in future drug development.
- Innovative Drug Development: ALA-002, a patented MDMA formulation recognized by the FDA, aims to improve cardiovascular safety and reduce abuse risks while maintaining the therapeutic effects associated with MDMA-assisted treatment, potentially playing a pivotal role in future neuropsychiatric therapies.
- Market Potential: This deal positions Jupiter to capitalize on the rapidly growing psychedelic therapeutics market, which is expected to evolve into a multi-billion-dollar industry in the U.S., indicating the company's strategic focus on emerging medical fields.
- Positive Stock Reaction: Shares of JUNS surged over 50% in early trading, marking the largest single-day gain in nearly a year, with retail sentiment shifting from neutral to extremely bullish, demonstrating strong investor confidence in the company's future prospects.
See More
UK Launches Investment Campaign Featuring Savvy the Squirrel
- Campaign Launch: Chancellor Rachel Reeves and CEO Julia Hoggett of the London Stock Exchange have initiated a £20 million investment campaign aimed at encouraging more Britons to invest, with expectations of significantly enhancing public awareness of investment over the next three years.
- Target Audience Defined: The campaign specifically targets approximately 7 million adults holding over £10,000 in cash savings, aiming to shift their perception of investing and reduce the tendency to leave funds idle in cash, thereby driving economic growth and improving personal financial security.
- Broad Industry Support: The initiative has garnered backing from major financial institutions, including Hargreaves Lansdown and St James's Place, demonstrating a collective effort within the financial services sector to elevate investment awareness and strengthen industry collaboration.
- Rich Historical Context: The launch of this campaign starkly contrasts with the investment boom of the 1980s, when the UK government spurred public interest in stock investments through privatization policies, reflecting the evolving investment culture and its potential economic implications today.
See More
